Stay updated on Setmelanotide in BBS and AS for Obesity Clinical Trial
Sign up to get notified when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.

Latest updates to the Setmelanotide in BBS and AS for Obesity Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check11 days agoChange DetectedNo visible additions or deletions detected; the page content appears unchanged.SummaryDifference0.2%

- Check19 days agoChange DetectedAdded a new publication citation to the Publications section: Argente J, Haqq AM, Schorfheide JL, Touchot N, Huber C, Wiedemann U, Pomeroy J; Phase 3 BBS Trial Investigators. Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity (Silver Spring). 2026 Feb 17. Online ahead of print.SummaryDifference0.2%

- Check26 days agoChange DetectedResults have been posted for the phase 3 study, including primary and secondary outcomes and related efficacy data.SummaryDifference0.2%

- Check33 days agoChange DetectedThe page now displays revision v3.4.2 and the prior funding-lapse notice (v3.4.1) has been removed.SummaryDifference0.6%

- Check40 days agoChange DetectedA funding-status notice was added and the page revision updated to v3.4.1 (replacing v3.4.0). These changes are administrative and do not affect study data, eligibility, or core content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

Stay in the know with updates to Setmelanotide in BBS and AS for Obesity Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.